PSMA-PET detects more oligometastatic prostate cancer than conventional imaging

A multicenter retrospective study of 255 patients with intermediate- to high-risk prostate cancer compared PSMA-PET with conventional imaging (CT and bone scintigraphy) performed within four months of each other. PSMA-PET identified oligometastatic disease in 11.4% of patients versus 6.7% with conventional imaging, and a multidisciplinary review found the intended treatment plan changed in 36.5% of cases. The authors note the study lacked an independent reference standard or follow-up, so it does not establish improved diagnostic accuracy or any survival benefit.

Most relevant for: Patients with intermediate- to high-risk prostate cancer being staged for possible curative versus systemic treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.